ArticleMicrobiology spectrum2026
Metallo-beta-lactamase α-helix fragment modified peptide N10 is a multifunctional antimicrobial peptide.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Metallo-beta-lactamases (MBLs) increase the spread of drug resistance among bacteria worldwide and have severely limited the efficacy of β-lactam antibiotics. To develop alternative therapeutics, we used the MBL α-helix fragment as the original peptide, which is the main reason for carbapenem resistance, and modified it into D-amino acid to replace cyclic peptide N10. The antibacterial effect of N10 was detected through the broth microdilution method and time-kill curve and growth curve detection, and the effective minimum inhibitory concentrations (MICs) of N10 to bacteria ranged from 2 to 16 μg/mL. Based on the fluorescence microscopy, hydrogen ion SEM and TEM results, N10 showed extensive membrane damage and structural collapse. In the cell infection model, N10 decreased the levels of ROS and inflammatory factors to near-control levels at 2× MIC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.